2026年，药品零售企业将迎来一轮并购与重组。 近日，商务部、国家发展改革委、工业和信息化部、国家卫生健康委等9部门发布《关于促进药品零售 行业高质量发展的意见》(以下简称《意见》)，鼓励药品零售企业依法开展横向并购与重组。 《意见》指出，支持零售药店进行兼并重组。鼓励药品零售企业依法开展横向并购与重组。鼓励各地优 化营商环境，对于被整合的连锁或单体药店，优化《药品经营许可证》申请核发流程。涉及医保资质变 更的，允许原医保资质继续存续和使用，新医保资质正式开通后，注销原医保资质。 药品零售企业是指将购进的药品直接销售给消费者的经营主体，其核心特征是面向终端消费者进行药品 销售。在实际经营中，这类企业最常见的组织形式就是零售药店，包括单体药店和药品零售连锁企业的 门店。零售药店作为药品流通的"最后一公里"，直接连接患者与药品供应，其健康发展关系到公众用药 可及性、价格合理性及服务质量。 三是兼并重组障碍多，整合效率低。药店并购涉及《药品经营许可证》变更、医保资质衔接等复杂流 程。过去，收购后需重新申请许可证，需要耗时数月；医保资质变更期间易出现"空窗期"，购药无法刷 医保，导致患者流失、收入下滑，抑制企业整合意 ...

Core Viewpoint - The recent policy document issued by multiple government departments aims to promote high-quality development in the pharmaceutical retail industry, leading to a surge in stock prices of major pharmacy chains in the A-share market [1][3]. Group 1: Policy Measures - The policy document outlines 18 specific measures to enhance the pharmaceutical retail sector, focusing on professionalization, digitalization, and regulatory compliance [1]. - Key initiatives include improving pharmacy service capabilities, supporting mergers and acquisitions among retail pharmacies, and fostering a fair competitive market environment [2]. Group 2: Market Impact - The policy is expected to drive mergers and acquisitions, increasing industry concentration and facilitating the transition of pharmacies from "drug sales" to "comprehensive services" [2]. - Leading pharmacy chains such as Yifeng Pharmacy and Dacelins have seen significant stock price increases, with Yifeng's store count projected to exceed 14,666 by September 2025, and Dacelins operating 17,385 stores [3]. Group 3: Benefits to Other Companies - Other pharmaceutical companies like Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong are anticipated to benefit from the integration of wholesale and retail operations, enhancing their revenue potential [3]. - The policy encourages retail pharmacies to enhance their service capabilities, which may benefit digital and supply chain service providers in the healthcare sector [4].

目前，参保人员凭定点医药机构处方在定点零售药店购买医保目录内药品发生的费用可由医保基金按规 定支付。此次《意见》的出台，将进一步优化定点零售药店门诊统筹服务。《意见》提到，优化医保基 金与零售药店的结算方式，有效压缩结算时长，提升结算效率。优化医保定点零售药店资源配置规划， 结合一刻钟便民生活圈建设，推动医保定点药店合理布局。 此外，《意见》鼓励行业协会或区域医药流通龙头企业牵头，引导药品零售企业参与药品集中带量采 购。针对其他药品，鼓励零售药店整合采购需求，开展联合采购，实现量价挂钩，提升议价能力。 《意见》还特别提到引导商业健康保险与基本医疗保险协同发展，支持保险机构开发适配药品零售场景 的商业健康保险产品，满足群众多元化保障需求。针对高值药品、器械，支持药品零售企业与商业保险 机构建立风险共担、便捷高效的支付协同机制，切实降低患者支付压力。 针对应急保供需求，《意见》明确将强化零售药店"哨点"功能，鼓励大型连锁企业建立药品需求动态预 测和低库存预警机制。鼓励在疫情、灾情等突发情况下开展24小时营业、拆零销售、免费送药等服务， 稳定药品价格并引导合理用药。 推广药品比价工具应用 在优化行业结构方面，《意见 ...

Core Viewpoint - The Chinese government is promoting the integration of drug wholesale and retail operations to enhance the quality and efficiency of the pharmaceutical distribution industry, marking a shift towards a more consolidated and high-quality development phase in the sector [1][4]. Group 1: Policy Initiatives - The State Council issued guidelines in December 2024 to improve the regulatory quality of new pharmaceutical distribution models [1][4]. - Inner Mongolia has issued its first integrated drug wholesale and retail license, indicating a significant step in the implementation of integrated operations [5]. - Jiangxi Province has introduced 13 policy measures to support the high-quality development of the drug retail chain industry, focusing on streamlining approval processes and encouraging storage and distribution [6][7]. - Hunan Province has launched new regulations to encourage integrated drug wholesale and retail operations, aiming to enhance the pharmaceutical distribution system [2][7]. - Shanxi Province is promoting various operational models, including entrusted storage and distribution, with 122 drug wholesale companies meeting modern logistics standards [3][7]. Group 2: Market Impact - The issuance of the first integrated license in Inner Mongolia signifies the optimization of the pharmaceutical distribution landscape and the activation of market vitality [5]. - The measures in Jiangxi are expected to foster a better business environment and support the development of the private economy, enhancing health services and ensuring drug quality [6][7]. - Hunan's new regulations are seen as a critical step towards invigorating the pharmaceutical industry in the province [2][7]. - Shanxi's support for multiple operational models is aimed at stimulating market activity, with a reported 39.22% coverage of modern logistics among drug wholesale companies [3][7].

Core Viewpoint - Cinda Securities reports that China National Pharmaceutical Group (National Pharmaceutical Holdings) is nearing the end of its inefficient business adjustments, with profit improvements expected by Q3 2025. The company is benefiting from increased industry concentration and the development of innovative businesses, leading to a gradual increase in dividend payout ratios and a current valuation below historical averages. The initial coverage gives the company a "Buy" investment rating [1]. Group 1: Profit Improvement and Business Adjustments - The adjustment of inefficient businesses is close to completion, with significant profit improvements observed. In Q3 2025, the sales expense ratio and management expense ratio decreased, resulting in a net profit margin increase of 0.2 percentage points, with a year-on-year growth rate of 17% in net profit attributable to shareholders [2]. - The year 2025 marks the end of the 14th Five-Year Plan and the base year for the 15th Five-Year Plan, focusing on quality improvement and business structure optimization. The company is expected to perform well in 2026, with profits likely to exceed expectations [2]. - The company has steadily increased its dividend payout ratio over the past four years, from 28.1% in 2021 to 30.98% in 2024, with an average annual increase of 0.96 percentage points. The average dividend yield over the past five years is 4.45%, and the current price-to-book (PB) ratio is approximately 0.71, below the five-year average of 0.81 [2][4]. Group 2: Industry Concentration and Growth Drivers - The concentration of the distribution industry has increased, with the market share of the top four companies rising from 38.38% in 2019 to 42.69% in 2023, with National Pharmaceutical Holdings holding a 20.36% market share in 2023. The compound annual growth rate (CAGR) of the company's pharmaceutical distribution revenue is approximately 7% from 2018 to 2024, with projected revenue of about 424.6 billion yuan in 2024 [3]. - Growth drivers for pharmaceutical distribution include increased industry concentration, optimization of product structure towards high-demand and high-value products, and the promotion of innovative service development. The CAGR for medical device distribution revenue is approximately 15.69%, with projected revenue of about 117.5 billion yuan in 2024 [3]. - In the retail sector, the company is advancing its "integrated wholesale and retail" strategy, with a CAGR of approximately 16% in retail revenue from 2018 to 2024. The revenue growth for the National Pharmacy is projected at 12.52%, while specialized pharmacies are expected to grow at a CAGR of about 23.64% [3]. Group 3: Future Planning and Governance Changes - The governance structure of the National Pharmaceutical Group underwent changes in 2024, with new leadership appointed. The company aims to achieve a strategic goal of becoming a top 100 company with a trillion yuan in revenue by the end of the 14th Five-Year Plan, and the planning for the 15th Five-Year Plan is set to begin in 2025 [4]. - The company’s dividend payout ratio has shown a steady increase, with a slight decline in the dividend yield to 3.47% in 2024 due to a decrease in profits. The current PB ratio is approximately 0.71, which is below the five-year average of 0.81 [4]. Group 4: Revenue and Profit Forecast - The company is projected to achieve revenues of 577.19 billion yuan, 597.83 billion yuan, and 619.32 billion yuan for the years 2025 to 2027, with year-on-year growth rates of -1%, 4%, and 4%, respectively. The net profit attributable to shareholders is expected to be 8.08 billion yuan, 8.75 billion yuan, and 9.52 billion yuan, with growth rates of 15%, 8%, and 9% [5].

Core Viewpoint - The company is expected to improve profitability and operational efficiency as it approaches the end of its low-efficiency business adjustments by Q3 2025, with a projected net profit growth of 17% in that quarter [1] Group 1: Financial Performance - In Q3 2025, the company's sales expense ratio and management expense ratio decreased, leading to a net profit margin increase of 0.2 percentage points [1] - The company's dividend payout ratio has steadily increased from 28.1% in 2021 to 30.98% in 2024, with an average annual increase of 0.96 percentage points [1][3] - The company's current price-to-book (PB) ratio is approximately 0.71, which is lower than the five-year average of 0.81 [1][3] Group 2: Industry Trends - The concentration of the pharmaceutical distribution industry has increased from 38.38% in 2019 to 42.69% in 2023, with the company holding a market share of 20.36% in 2023 [2] - The compound annual growth rate (CAGR) for the company's pharmaceutical distribution revenue is projected to be around 7% from 2018 to 2024, with expected revenue of approximately 424.6 billion yuan in 2024 [2] - The company's medical device distribution revenue is expected to grow at a CAGR of about 15.69% from 2018 to 2024, reaching approximately 117.5 billion yuan in 2024 [2] Group 3: Strategic Initiatives - The company is focusing on enhancing quality and efficiency while optimizing its business structure in preparation for the "14th Five-Year Plan" conclusion and the "15th Five-Year Plan" initiation [1][3] - The company is implementing a "wholesale and retail integration" strategy to deepen its dual-brand strategy with professional pharmacies and Guoda pharmacies [2] - The company anticipates improvements in profitability for Guoda pharmacies by optimizing underperforming stores [2] Group 4: Future Projections - The company forecasts revenues of 577.19 billion yuan, 597.83 billion yuan, and 619.32 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 8.08 billion yuan, 8.75 billion yuan, and 9.52 billion yuan [4] - The projected price-to-earnings (PE) ratios for 2025, 2026, and 2027 are 7.27, 6.71, and 6.17, respectively [4]